| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/17/2023 | 252.26% | Goldman Sachs | $21 → $18 | Maintains | Buy |
| 11/16/2023 | 36.99% | UBS | $11 → $7 | Maintains | Neutral |
| 11/16/2023 | 17.42% | Roth MKM | $10 → $6 | Maintains | Neutral |
| 11/16/2023 | 252.26% | Goldman Sachs | $21 → $18 | Maintains | Buy |
| 11/16/2023 | 36.99% | Northland Capital Markets | $25 → $7 | Downgrades | Outperform → Market Perform |
| 11/16/2023 | 95.7% | Raymond James | $20 → $10 | Maintains | Outperform |
| 10/17/2023 | 173.98% | Morgan Stanley | $22 → $14 | Maintains | Equal-Weight |
| 10/16/2023 | 134.84% | B of A Securities | $31 → $12 | Downgrades | Buy → Neutral |
| 10/12/2023 | 310.97% | Goldman Sachs | $33 → $21 | Maintains | Buy |
| 10/11/2023 | 95.7% | Roth MKM | $25 → $10 | Downgrades | Buy → Neutral |
| 10/03/2023 | 291.4% | Raymond James | $28 → $20 | Maintains | Outperform |
| 10/02/2023 | 154.41% | UBS | → $13 | Initiates Coverage On | → Neutral |
| 09/21/2023 | 389.25% | Roth MKM | → $25 | Reiterates | Buy → Buy |
| 09/06/2023 | 330.54% | Morgan Stanley | $30 → $22 | Maintains | Equal-Weight |
| 08/14/2023 | 624.08% | Goldman Sachs | $43 → $37 | Maintains | Buy |
| 08/11/2023 | 447.96% | Raymond James | $34 → $28 | Maintains | Outperform |
| 08/11/2023 | 624.08% | Goldman Sachs | $43 → $37 | Maintains | Buy |
| 07/17/2023 | 487.1% | Morgan Stanley | $32 → $30 | Maintains | Equal-Weight |
| 06/14/2023 | 682.79% | Roth MKM | $21 → $40 | Upgrades | Neutral → Buy |
| 05/17/2023 | 682.79% | Northland Capital Markets | $31 → $40 | Maintains | Outperform |
| 05/12/2023 | 545.81% | B of A Securities | $37 → $33 | Maintains | Buy |
| 05/11/2023 | 741.5% | Goldman Sachs | $31 → $43 | Maintains | Buy |
| 05/11/2023 | 565.38% | Raymond James | $30 → $34 | Maintains | Outperform |
| 04/05/2023 | 487.1% | Raymond James | $24 → $30 | Maintains | Outperform |
| 04/03/2023 | 526.24% | Morgan Stanley | $21 → $32 | Maintains | Equal-Weight |
| 03/09/2023 | 506.67% | Goldman Sachs | $27 → $31 | Maintains | Buy |
| 03/08/2023 | 310.97% | Roth MKM | $19 → $21 | Maintains | Neutral |
| 03/08/2023 | 506.67% | Northland Capital Markets | $24 → $31 | Maintains | Outperform |
| 03/08/2023 | 369.68% | Raymond James | $22 → $24 | Maintains | Outperform |
| 01/04/2023 | 330.54% | Raymond James | → $22 | Upgrades | Market Perform → Outperform |
| 09/08/2022 | 428.39% | Goldman Sachs | $9 → $27 | Upgrades | Sell → Buy |
| 08/22/2022 | 76.13% | Goldman Sachs | $8 → $9 | Maintains | Sell |
| 08/18/2022 | 310.97% | Morgan Stanley | $14 → $21 | Maintains | Equal-Weight |
| 08/16/2022 | — | Raymond James | Downgrades | Outperform → Market Perform | |
| 08/08/2022 | 330.54% | Northland Capital Markets | → $22 | Initiates Coverage On | → Outperform |
| 05/27/2022 | 252.26% | Raymond James | $23 → $18 | Maintains | Outperform |
| 01/13/2022 | 173.98% | Morgan Stanley | $18 → $14 | Maintains | Equal-Weight |
| 12/03/2021 | 350.11% | B of A Securities | $22 → $23 | Upgrades | Neutral → Buy |
| 10/05/2021 | 350.11% | Raymond James | $26 → $23 | Downgrades | Strong Buy → Outperform |
| 08/25/2021 | 252.26% | Morgan Stanley | $17 → $18 | Maintains | Equal-Weight |
| 08/16/2021 | 232.69% | Roth Capital | $19 → $17 | Maintains | Neutral |
| 08/13/2021 | 408.82% | Raymond James | $33 → $26 | Maintains | Strong Buy |
| 08/09/2021 | 232.69% | Morgan Stanley | → $17 | Initiates Coverage On | → Equal-Weight |
| 05/06/2021 | 545.81% | Raymond James | $45 → $33 | Upgrades | Outperform → Strong Buy |
| 04/12/2021 | 350.11% | Roth Capital | → $23 | Downgrades | Buy → Neutral |
| 04/07/2021 | 780.64% | Raymond James | $60 → $45 | Maintains | Outperform |
| 02/11/2021 | 1074.19% | Raymond James | $40 → $60 | Maintains | Outperform |
| 01/19/2021 | 741.5% | Roth Capital | → $43 | Initiates Coverage On | → Buy |
| 01/08/2021 | 682.79% | Raymond James | $25 → $40 | Maintains | Outperform |
| 11/10/2020 | — | Raymond James | Upgrades | Market Perform → Outperform | |
| 10/16/2020 | 193.55% | Goldman Sachs | $18 → $15 | Downgrades | Neutral → Sell |
| 08/28/2020 | 252.26% | Goldman Sachs | → $18 | Initiates Coverage On | → Neutral |
What is the target price for Maxeon Solar Technologies (MAXN)?
The latest price target for Maxeon Solar Technologies (NASDAQ: MAXN) was reported by Goldman Sachs on November 17, 2023. The analyst firm set a price target for $18.00 expecting MAXN to rise to within 12 months (a possible 252.26% upside). 30 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Maxeon Solar Technologies (MAXN)?
The latest analyst rating for Maxeon Solar Technologies (NASDAQ: MAXN) was provided by Goldman Sachs, and Maxeon Solar Technologies maintained their buy rating.
When is the next analyst rating going to be posted or updated for Maxeon Solar Technologies (MAXN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Maxeon Solar Technologies, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Maxeon Solar Technologies was filed on November 17, 2023 so you should expect the next rating to be made available sometime around November 17, 2024.
Is the Analyst Rating Maxeon Solar Technologies (MAXN) correct?
While ratings are subjective and will change, the latest Maxeon Solar Technologies (MAXN) rating was a maintained with a price target of $21.00 to $18.00. The current price Maxeon Solar Technologies (MAXN) is trading at is $5.11, which is out of the analyst's predicted range.